Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Age as a Risk Stratification Factor in Surgically Treated Low-Risk Indeterminate Thyroid Nodules: Insight From the TIRETA Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gatta Elisa, Pirola Ilenia, Bozzola Anna Maria, Lombardi Davide, Morandi Riccardo, Gandossi Elena, Enezari Loubna, Manelli Sara, Zoccoletto Caterina, Casella Claudio, Cappelli Carlo
Аннотация
OBJECTIVES: To evaluate whether age acts as a clinically meaningful risk stratification factor in surgically treated TIR3A/Bethesda III nodules.
METHODS: We retrospectively reviewed consecutive adult patients with TIR3A cytology who underwent thyroid surgery between 2015 and 2025 at a single tertiary center. Only cases with definitive histology were included. The primary outcome was malignancy at final histology. Age was analyzed as both a continuous and categorical variable using univariable and multivariable logistic regression models. Nonlinear associations were explored with restricted cubic splines. Discriminative performance was assessed by receiver operating characteristic curve analysis and decision curve analysis.
RESULTS: Among 435 surgically treated patients (mean age 54 ± 14 years; 23.7% male), 76 (17.5%) had differentiated thyroid cancer. Increasing age was independently associated with a lower risk of malignancy (adjusted OR per year 0.98; 95% CI 0.96-0.99; P = .015). Age demonstrated modest discriminative performance (AUC 0.608; 95% CI 0.536-0.681). Model-based estimates indicated that age alone was associated with an absolute shift in malignancy probability of approximately 8-10 percentage points between 40 and 60 years.
CONCLUSIONS: In TIR3a/Bethesda III nodules, age functions as a clinically meaningful risk modifier rather than a stand-alone diagnostic tool. Although insufficient to guide surgery independently, age may help contextualize malignancy probability and support shared decision-making, particularly when molecular testing is unavailable or inconclusive.
METHODS: We retrospectively reviewed consecutive adult patients with TIR3A cytology who underwent thyroid surgery between 2015 and 2025 at a single tertiary center. Only cases with definitive histology were included. The primary outcome was malignancy at final histology. Age was analyzed as both a continuous and categorical variable using univariable and multivariable logistic regression models. Nonlinear associations were explored with restricted cubic splines. Discriminative performance was assessed by receiver operating characteristic curve analysis and decision curve analysis.
RESULTS: Among 435 surgically treated patients (mean age 54 ± 14 years; 23.7% male), 76 (17.5%) had differentiated thyroid cancer. Increasing age was independently associated with a lower risk of malignancy (adjusted OR per year 0.98; 95% CI 0.96-0.99; P = .015). Age demonstrated modest discriminative performance (AUC 0.608; 95% CI 0.536-0.681). Model-based estimates indicated that age alone was associated with an absolute shift in malignancy probability of approximately 8-10 percentage points between 40 and 60 years.
CONCLUSIONS: In TIR3a/Bethesda III nodules, age functions as a clinically meaningful risk modifier rather than a stand-alone diagnostic tool. Although insufficient to guide surgery independently, age may help contextualize malignancy probability and support shared decision-making, particularly when molecular testing is unavailable or inconclusive.